The gist

• Forces the FDA to modernize biosimilar drug factory inspections using remote tools and foreign partnerships, aiming to speed cheaper biologic medicines to market.

Who wins, who loses

• Wins: patients needing affordable biologics, biosimilar manufacturers, FDA inspectors gaining flexible tools.
• Loses: brand-name biologic makers facing faster generic competition; critics worried about reduced in-person oversight.

What it does

• Requires FDA public meeting within 180 days on mutual recognition agreements with trusted foreign regulators.
• Mandates report to Senate and House committees 180 days after that meeting.
• Orders FDA to expand remote regulatory assessments under June 2025 guidance.
• Requires a strategic plan within 1 year on domestic inspection staffing and communication.

Why should I care?

Biosimilars treat serious conditions like cancer and diabetes at lower prices than brand-name biologics. Supporters say modernizing inspections cuts delays, lowering drug costs for families. Critics argue remote inspections and foreign partnerships might miss safety problems that in-person visits catch. Where do you land? Vote below and use "Tell Your Rep" to make sure your voice reaches Congress.